Bozeman, MT (March 4, 2004) — Golden Helix, Inc. announced today that it has entered into an agreement with DigiGenomics Co., Ltd. to market Golden Helix’ proprietary HelixTree® genetics analysis software and ChemTree® chemoinformatics software in Taiwan. DigiGenomics Co., Ltd is an informatics-driven biotech service company dedicated to resolving research bottlenecks. DigiGenomics’ scientific service team brings not only bio-informatics products that aid in research, but the professional services necessary to create solutions in the drug discovery industry. Taiwan is a country that has an infrastructure very favorable to pharmaceutical development. It enjoys a solid legal system that is particularly strong in IP protection; a highly educated workforce, especially in the life sciences; has a modern and very competitive industrial development structure; and abundant venture capital resources.
“Pharmacogenomics and high-throughput screening are getting more and more attention in US as well as in Taiwan,” said Joey Chen, President of DigiGenomics Co., Ltd. “As a pioneering informatics-driven biotech company in this area, DigiGenomics aims to serve our customers with leading solutions. The professionalism of solutions from Golden Helix perfectly aligns with our expectation. We do believe that the partnership definitely benefit to both parties.”
“DigiGenomics Co. Ltd. exposes Golden Helix to another vibrant life sciences market,” said Christophe Lambert, CEO and President of Golden Helix. “As a leader in the distribution and support of life sciences software in Taiwan, they are a natural fit with us. They understand the needs of both the commercial and academic markets and how Golden Helix software can bring great value to the research and drug discovery process in Taiwan. Both companies have focused on accelerating the drug discovery pipeline through maximizing the intelligent deployment of bio-informatics.”
Golden Helix Software offers significant benefits to pharmaceutical companies and researchers:
HelixTree® software is used to relate thousands of interacting genes and environmental factors to clinical trials outcomes. Scientists use HelixTree for association studies, to determine phenotype/genotype relationships, understand the mechanics of human genetic variation, discover sub-population side effects for existing drugs, and create new, optimized drugs that maximize efficacy and minimize side effects.
ChemTree® software facilitates intelligent, target specific compound selection for High Throughput Screening (HTS). ChemTree’s ability to “cherry pick” promising compounds increases screening hit rates by an order of magnitude while reducing the number of compounds screened by 80%. The software is also used to study structural activity relationships (SARs) to assist chemists in lead discovery.
About Digigenomics Co., Ltd.
Founded in 2000, DigiGenomics (http://www.digigenomics.com/) is a groundbreaking informatics-based biotech company in Taiwan, focusing on the management of biosciences information and drug discovery services using bio-informatics research. DigiGenomics integrates technologies from computer science, genomics and proteomics, to provide scientists with the best opportunity to advance their research across the whole drug discovery pipeline from the initial target identification and validation to the later stages of drug discovery and development. DigiGenomics’ foundation of uncompromising integrity coupled with their innovative scientific and technological professional workforce and laboratory capacity has led to one of the creation of one of Taiwan’s biotech sector’s success stories.
About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.